The good news for Sun Pharma is that it's closed the books on one more legal problem it inherited from its Ranbaxy Laboratories buyout eight years ago. The bad: It's going to cost the generics maker $485 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,